drugset / Trial / NCT03013751
A Extension Study of Udenafil in Adolescents
Phase 3
Completed
301 enrolled
Mezzion Pharma Co. Ltd
National Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a 12-month (52 week) safety extension study to supplement the FUEL Phase III clinical trial to provide safety information regarding the long-term use of udenafil in adolescents with single ventricle congenital heart disease.
Timeline
- Start
- 2017-02-06
- Primary completion
- 2019-12-30
- Completion
- 2022-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Udenafil | Small molecule | — | — |